半乳糖凝集素9(GAL9)檢測試劑盒(酶聯(lián)免疫吸附試驗(yàn)法)
ELISA Kit for Galectin 9 (GAL9)
LGALS9; Ecalectin; Lectin,Galactoside-Binding Soluble 9; Tumor antigen HOM-HD-21
- 編號(hào)USEA309Hu
- 物種Homo sapiens (Human，人) 相同的名稱，不同的物種。
- 實(shí)驗(yàn)方法雙抗夾心
- 反應(yīng)時(shí)長3h
- 檢測范圍78-5,000pg/mL
- 靈敏度最小可檢測劑量小于等于33pg/mL.
- 樣本類型serum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids
- 下載 英文說明書 中文說明書
- 規(guī)格 48T96T 96T*5 96T*10 96T*100
- 價(jià)格 ¥ 1193 ¥ 1704 ¥ 7668 ¥ 14484 ¥ 119280
- 欲了解實(shí)際交易價(jià)格和更多情況，請與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
實(shí)驗(yàn)結(jié)果圖
-
標(biāo)準(zhǔn)曲線圖
-
通過ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
特異性
本試劑盒用于檢測半乳糖凝集素9(GAL9)，經(jīng)檢測與其它相似物質(zhì)無明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來源的限制，不可能完成對所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測，因此本試劑盒有可能與未經(jīng)檢測的其它物質(zhì)有交叉反應(yīng)。
回收率
分別于定值血清及血漿樣本中加入一定量的半乳糖凝集素9(GAL9)（加標(biāo)樣品），重復(fù)測定并計(jì)算其均值，回收率為測定值與理論值的比率。
| 樣本 | 回收率范圍(%) | 平均回收率(%) |
| serum(n=5) | 96-104 | 101 |
| EDTA plasma(n=5) | 87-101 | 90 |
| heparin plasma(n=5) | 87-97 | 93 |
精密度
精密度用樣品測定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差：取同批次試劑盒對低、中、高值定值樣本進(jìn)行定量檢測,每份樣本連續(xù)測定20 次，分別計(jì)算不同濃度樣本的平均值及SD值。
批間差：選取3個(gè)不同批次的試劑盒分別對低、中、高值定值樣本進(jìn)行定量測定，每個(gè)樣本使用同一試劑盒重復(fù)測定8次，分別計(jì)算不同濃度樣本的平均值及SD值。
批內(nèi)差： CV<10%
批間差： CV<12%
線性
在定值血清及血漿樣本內(nèi)加入適量的半乳糖凝集素9(GAL9)，并倍比稀釋成1:2，1:4，1:8，1:16的待測樣本，線性范圍即為稀釋后樣本中半乳糖凝集素9(GAL9)含量的測定值與理論值的比率。
| 樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 93-105% | 95-102% | 84-91% | 79-101% |
| EDTA plasma(n=5) | 78-91% | 86-96% | 88-102% | 95-103% |
| heparin plasma(n=5) | 95-104% | 88-95% | 81-90% | 82-105% |
穩(wěn)定性
經(jīng)測定，試劑盒在有效期內(nèi)按推薦溫度保存，其活性降低率小于5%。
為減小外部因素對試劑盒破壞前后檢測值的影響，實(shí)驗(yàn)室的環(huán)境條件需盡量保持一致，尤其是實(shí)驗(yàn)室內(nèi)溫度、濕度及溫育條件。其次由同一實(shí)驗(yàn)員來進(jìn)行操作可減少人為誤差。
實(shí)驗(yàn)流程
1. 實(shí)驗(yàn)前標(biāo)準(zhǔn)品、試劑及樣本的準(zhǔn)備；
2. 加樣（標(biāo)準(zhǔn)品及樣本）100µL，37°C孵育1小時(shí)；
3. 吸棄，加檢測溶液A100µL，37°C孵育1小時(shí)；
4. 洗板3次；
5. 加檢測溶液B100µL，37°C孵育30分鐘；
6. 洗板5次；
7. 加TMB底物90µL，37°C孵育10-20分鐘；
8. 加終止液50µL，立即450nm讀數(shù)。
實(shí)驗(yàn)原理
將半乳糖凝集素9(GAL9)抗體包被于96孔微孔板中，制成固相載體，向微孔中分別加入標(biāo)準(zhǔn)品或標(biāo)本，其中的半乳糖凝集素9(GAL9)與連接于固相載體上的抗體結(jié)合，然后加入生物素化的半乳糖凝集素9(GAL9)抗體，將未結(jié)合的生物素化抗體洗凈后，加入HRP標(biāo)記的親和素，再次徹底洗滌后加入TMB底物顯色。TMB在過氧化物酶的催化下轉(zhuǎn)化成藍(lán)色，并在酸的作用下轉(zhuǎn)化成最終的黃色。顏色的深淺和樣品中的半乳糖凝集素9(GAL9)呈正相關(guān)。用酶標(biāo)儀在450nm波長下測定吸光度(O.D.值)，計(jì)算樣品濃度。
贈(zèng)品
增值服務(wù)
相關(guān)產(chǎn)品
| 編號(hào) | 適用物種：Homo sapiens (Human，人) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| URPA309Hu01 | 半乳糖凝集素9(GAL9)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| UAPA309Hu01 | 半乳糖凝集素9(GAL9)活性蛋白 | Cell?culture;?Activity?Assays. |
| UAPA309Hu61 | 半乳糖凝集素9(GAL9)活性蛋白 | Cell?culture;?Activity?Assays. |
| UEPA309Hu61 | 半乳糖凝集素9(GAL9)真核蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| UPAA309Hu02 | 半乳糖凝集素9(GAL9)多克隆抗體 | WB; IHC |
| UPAA309Hu01 | 半乳糖凝集素9(GAL9)多克隆抗體 | WB; IHC; ICC/IF |
| UMAA309Hu22 | 半乳糖凝集素9(GAL9)單克隆抗體 | WB; IHC; ICC; IP. |
| USEA309Hu | 半乳糖凝集素9(GAL9)檢測試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| USCA309Hu | 半乳糖凝集素9(GAL9)檢測試劑盒(化學(xué)發(fā)光免疫分析法) | Chemiluminescent immunoassay for Antigen Detection. |
| ULMA309Hu | 半乳糖凝集素9(GAL9)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| American Journal of Nephrology | Temporal Increases in Urinary Carboxymethyllysine Correlate with Albuminuria Development in Diabetes [Karger: 328581] |
| Clinical Immunology | Galectin-9 administration ameliorates CVB3 induced myocarditis by promoting the proliferation of regulatory T cells and alternatively activated Th2 cells [ScienceDirect: S1521661611001057] |
| Renal Failure | Rat Renal Interstitial Fibroblasts Affect the Th1/Th2 Profile In Vitro [Pubmed: 22013937] |
| BMC Nephrol | Serum galectin-9 levels are elevated in the patients with type 2 diabetes and chronic kidney disease [PubMed: 23339460] |
| Retrovirology | Dysregulated Tim-3 expression on natural killer cells is associated with increased Galectin-9 levels in HIV-1 infection [PubMed: PMC3750478] |
| PLoS One. | Upregulation of the Tim-3/Galectin-9 Pathway of T Cell Exhaustion in Chronic Hepatitis B Virus Infection [PubMed: PMC3480425] |
| PLoS Pathogens | Galectin-9 and IL-21 Mediate Cross-regulation between Th17 and Treg Cells during Acute Hepatitis C [PubMed: PMC3688567] |
| PLOS ONE | Graves’ Disease Is Associated with a Defective Expression of the Immune Regulatory Molecule Galectin-9 in Antigen-Presenting Dendritic Cells [PubMed: 25880730] |
| Advances in Experimental?Medicine?and?Biology | Molecules of Damage-Associated Patterns in Bronchoalveolar Lavage Fluid and Serum in Chronic Obstructive Pulmonary Disease [Pubmed:29429028] |
| Journal?of?Microbiology,?Immunology?and?Infection | Galectin-9-like from Angiostrongylus cantonensis young adult worms modulates eosinophil chemotaxis in vitro [Doi: 10.1016/j.jmii.2018.09.010] |
| Oncology?Letters | The effects of Tim?3 activation on T?cells in gastric cancer progression [] |
| Scientific Reports | Circulating levels of PD-L1 and Galectin-9 are associated with patient survival in surgically treated Hepatocellular Carcinoma independent of their intra?… [Pubmed: 31337865] |
| Biomolecules | Blood Levels of Galectin-9, an Immuno-Regulating Molecule, Reflects the Severity for the Acute and Chronic Infectious Diseases. Biomolecules 2021, 11, 430 [33804076] |
| Medicine | Regulatory T cells, damage-associated molecular patterns, and myeloid-derived suppressor cells in bronchoalveolar lavage fluid interlinked with chronic obstructive?… [Pubmed:35687771] |
